Scancell Holdings plc (FRA:SCP)
Germany · Delayed Price · Currency is EUR 0.0800
-0.0005 (-0.62%)
Last updated: Jan 8, 2026, 8:08 AM CET
Scancell Holdings Employees
Scancell Holdings had 60 employees as of April 30, 2025. The number of employees decreased by 1 or -1.64% compared to the previous year.
Employees
60
Change (1Y)
-1
Growth (1Y)
-1.64%
Revenue / Employee
€92,272
Profits / Employee
€240,364
Market Cap
134.55M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Apr 30, 2025 | 60 | -1 | -1.64% |
| Apr 30, 2024 | 61 | 10 | 19.61% |
| Apr 30, 2023 | 51 | 11 | 27.50% |
| Apr 30, 2022 | 40 | 15 | 60.00% |
| Apr 30, 2021 | 25 | 3 | 13.64% |
| Apr 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Siemens Aktiengesellschaft | 317,562 |
| Deutsche Telekom AG | 198,194 |
| Mercedes-Benz Group AG | 175,264 |
| Bayerische Motoren Werke Aktiengesellschaft | 159,104 |
| Allianz SE | 156,626 |
| SAP SE | 109,121 |
| Siemens Energy AG | 98,995 |
| Deutsche Bank Aktiengesellschaft | 89,753 |
Scancell Holdings News
- 4 weeks ago - Scancell Holdings plc (SCNLF) Discusses SCOPE Phase II Data: iSCIB1+ Shows Improved Progression-Free Survival in Advanced Melanoma - Slideshow - Seeking Alpha
- 4 weeks ago - Scancell Holdings plc (SCNLF) Discusses SCOPE Phase II Data: iSCIB1+ Shows Improved Progression-Free Survival in Advanced Melanoma Transcript - Seeking Alpha
- 4 months ago - Scancell Holdings Plc (SCNLF) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Scancell reports Business Update and Financial Results for the Year Ended 30 April 2025 - GlobeNewsWire
- 6 months ago - Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody® iSCIB1+ - GlobeNewsWire
- 1 year ago - PharmaJet and Scancell Sign Strategic Partnership Agreement for Development and Commercialization of a Needle-free DNA Vaccine for Advanced Melanoma - Business Wire
- 2 years ago - PharmaJet Partner, Scancell, Announces Positive Data from the First Stage of its Phase 2 Trial of Advanced Melanoma DNA Vaccine delivered Needle-free - Business Wire